INT107315

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 22
Total Number 26
Disease Relevance 13.82
Pain Relevance 6.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (CCR5) plasma membrane (CCR5) cell-cell signaling (CCR5)
cytoplasm (CCR5) signal transducer activity (CCR5)
Anatomy Link Frequency
Monocytes 2
PDL-1 1
T cells 1
ovary 1
CCR5 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 264 100.00 Very High Very High Very High
chemokine 243 100.00 Very High Very High Very High
iatrogenic 4 99.98 Very High Very High Very High
Opioid 32 99.84 Very High Very High Very High
opioid receptor 12 99.44 Very High Very High Very High
Multiple sclerosis 49 96.52 Very High Very High Very High
rheumatoid arthritis 192 96.20 Very High Very High Very High
opiate 5 95.68 Very High Very High Very High
Inflammation 158 95.24 Very High Very High Very High
Parenteral administration 5 94.64 High High
Disease Link Frequency Relevance Heat
Acquired Immune Deficiency Syndrome Or Hiv Infection 1128 99.96 Very High Very High Very High
Infection 265 99.92 Very High Very High Very High
Cancer 101 99.32 Very High Very High Very High
Sprains And Strains 95 98.44 Very High Very High Very High
Carcinoma 6 97.36 Very High Very High Very High
Multiple Sclerosis 57 96.52 Very High Very High Very High
Rheumatoid Arthritis 193 96.20 Very High Very High Very High
Death 40 96.16 Very High Very High Very High
Disease 130 95.36 Very High Very High Very High
INFLAMMATION 167 95.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Monocytes from cancer patients displayed significantly reduced CCR5 levels and migration capacities in comparison to cells from healthy donors.
Negative_regulation (reduced) of CCR5 in Monocytes associated with cancer
1) Confidence 0.57 Published 2003 Journal FASEB J. Section Abstract Doc Link 12490541 Disease Relevance 0.64 Pain Relevance 0.16
Despite this, we found that the cross-desensitization of CCR5 by opioids was associated with a decrease in susceptibility to R5 but not X4 strains of HIV-1.
Negative_regulation (desensitization) of CCR5 associated with acquired immune deficiency syndrome or hiv infection, sprains and strains and opioid
2) Confidence 0.56 Published 2003 Journal J. Leukoc. Biol. Section Abstract Doc Link 12972507 Disease Relevance 0.90 Pain Relevance 0.62
CCR5 inhibitors are unlikely to be of benefit to patients harboring X4 viruses as the predominant or minority variant.
Negative_regulation (inhibitors) of CCR5
3) Confidence 0.55 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012555 Disease Relevance 0.85 Pain Relevance 0.03
We described previously that expression levels of the chemokine receptor, CCR5, and the beta2-integrin, Mac-1, were down-regulated on primary monocytes after incubation in supernatants from human carcinoma cell lines, and that this down-regulation resulted in impaired monocyte function with respect to migration and adhesion.
Negative_regulation (down-regulated) of CCR5 in monocyte associated with chemokine, carcinoma and adhesions
4) Confidence 0.42 Published 2003 Journal FASEB J. Section Abstract Doc Link 12490541 Disease Relevance 0.49 Pain Relevance 0.14
Studies were performed with primary monocytes and Chinese hamster ovary cells transfected with CCR5 and the micro-opioid receptor to determine whether cross-desensitization of CCR5 was a result of receptor internalization.
Negative_regulation (desensitization) of CCR5 in ovary associated with opioid receptor
5) Confidence 0.41 Published 2003 Journal J. Leukoc. Biol. Section Abstract Doc Link 12972507 Disease Relevance 0.51 Pain Relevance 0.55
Using radiolabeled-binding analysis, flow cytometry, and confocal microscopy, we found that the heterologous desensitization of CCR5 was not associated with a significant degree of receptor internalization.
Negative_regulation (desensitization) of CCR5
6) Confidence 0.41 Published 2003 Journal J. Leukoc. Biol. Section Abstract Doc Link 12972507 Disease Relevance 0.82 Pain Relevance 0.62
Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.
Negative_regulation (inactivation) of CCR5 associated with acquired immune deficiency syndrome or hiv infection, sprains and strains and opioid
7) Confidence 0.41 Published 2003 Journal J. Leukoc. Biol. Section Title Doc Link 12972507 Disease Relevance 0.36 Pain Relevance 0.51
The interference with HIV-1 uptake by heterologous desensitization of CCR5 suggests that HIV-1 interaction with this receptor is not passive but involves a signal transduction process.
Negative_regulation (desensitization) of CCR5 associated with acquired immune deficiency syndrome or hiv infection
8) Confidence 0.41 Published 2003 Journal J. Leukoc. Biol. Section Abstract Doc Link 12972507 Disease Relevance 1.04 Pain Relevance 0.39
Whether untoward consequences of the iatrogenic loss of the CCR5 receptor’s function, including an undue number of severe West Nile virus infections in WNV endemic areas, is a central question that will prove important to CCR5 antagonist use.


Negative_regulation (loss) of CCR5 receptor associated with iatrogenic, antagonist and infection
9) Confidence 0.41 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504054 Disease Relevance 0.31 Pain Relevance 0.37
UK-427,587’s mechanism of action was also confirmed to be strictly attributable to CCR5 blockade and no other antiviral means, eg, cell lysis.


Negative_regulation (blockade) of CCR5
10) Confidence 0.41 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504054 Disease Relevance 0.32 Pain Relevance 0.04
The CC-chemokine receptor 5 (CCR5) antagonists are a novel class of antiretroviral agents that prevent the entry of HIV into host cells by blocking the CCR5 coreceptor.
Negative_regulation (blocking) of CCR5 coreceptor associated with chemokine, antagonist and acquired immune deficiency syndrome or hiv infection
11) Confidence 0.41 Published 2007 Journal Core Evidence Section Abstract Doc Link PMC3012555 Disease Relevance 0.58 Pain Relevance 0.14
Individuals who lack a functional CCR5 gene are highly resistant to HIV-1 infection, and patients with only one copy of a functional CCR5 gene demonstrate delayed CD4 depletion and slower progress to AIDS and death (Liu et al. 1996; Samson et al. 1996; Moore et al. 2004).
Negative_regulation (lack) of CCR5 gene associated with acquired immune deficiency syndrome or hiv infection, death and infection
12) Confidence 0.41 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012555 Disease Relevance 0.73 Pain Relevance 0.19
Though a potent inhibitor of CCR5-tropic HIV-1 in vitro, development was curtailed due to the need for subcutaneous administration and the attendant difficulties with injection site reactions.
Negative_regulation (inhibitor) of CCR5-tropic associated with acquired immune deficiency syndrome or hiv infection
13) Confidence 0.40 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504054 Disease Relevance 0.25 Pain Relevance 0.22
Each is a mouse-derived but humanized monoclonal antibody capable of blocking CCR5 without activation of the receptor (Olson et al 1999; Roschke et al 2004).
Negative_regulation (blocking) of CCR5
14) Confidence 0.40 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504054 Disease Relevance 0.27 Pain Relevance 0.07
Firstly, selective inhibition of CCR5-tropic virus with CCR5 antagonist therapy may lead to an increased rate of emergence of CXCR4 variants in patients who harbor both the R5 and X4 virus, and vice versa.
Negative_regulation (inhibition) of CCR5-tropic associated with antagonist
15) Confidence 0.40 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012555 Disease Relevance 0.38 Pain Relevance 0.25
This agent acts through allosteric inhibition of the CCR5 receptor, preventing its interaction with gp120 and thus avoiding subsequent cellular entry by HIV.
Negative_regulation (inhibition) of CCR5 receptor associated with acquired immune deficiency syndrome or hiv infection
16) Confidence 0.37 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2952481 Disease Relevance 0.43 Pain Relevance 0.10
Maraviroc is a potent and selective antagonist of CCR5, with broad-spectrum anti-HIV-1 activity (Dorr et al. 2005; Wood & Armour 2005).
Negative_regulation (antagonist) of CCR5 associated with antagonist and acquired immune deficiency syndrome or hiv infection
17) Confidence 0.35 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012555 Disease Relevance 0.60 Pain Relevance 0.08
g DNA of each CD4 and CCR5 expression vectors, or CD4 plus empty vector as negative control, and 3 ?
Negative_regulation (vectors) of CCR5
18) Confidence 0.28 Published 2008 Journal Retrovirology Section Body Doc Link PMC2576352 Disease Relevance 0.27 Pain Relevance 0
Maraviroc prevents HIV entry by blocking CCR5 coreceptors.
Negative_regulation (blocking) of CCR5 associated with acquired immune deficiency syndrome or hiv infection
19) Confidence 0.27 Published 2010 Journal AIDS Res Ther Section Body Doc Link PMC2890503 Disease Relevance 0.63 Pain Relevance 0.12
MDCs and PDCs expression of CCR5 was also decreased to very low levels and this decease in chemokine receptors seemed to be due to the 24 h in vitro culture.
Negative_regulation (decreased) of CCR5 associated with chemokine
20) Confidence 0.25 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.30 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox